Quantisnow Logo
Dashboard

Adamas Announces New Employment Inducement Grants

$ADMS
Major Pharmaceuticals
Health Care
Get the next $ADMS alert in real time by email

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted eight new employees restricted stock units to acquire 106,500 shares of the company's common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

About Adamas Pharmaceuticals, Inc.

At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.

Get the next $ADMS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ADMS

DatePrice TargetRatingAnalyst
11/17/2021$8.50Outperform → Market Perform
Northland Capital Markets
10/12/2021Market Outperform → Market Perform
JMP Securities
10/12/2021$7.00 → $8.00Overweight → Neutral
Piper Sandler
10/12/2021$10.00 → $9.10Buy → Neutral
HC Wainwright & Co.
10/11/2021Outperform → Market Perform
William Blair
More analyst ratings

$ADMS
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

    ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). "Adamas fits squarely within our corporate development strategy, adding a late-stage commercial product with significant revenue," said Jack Khattar, President and CEO of Supernus Pharmaceuticals. "In addition, the acquisition adds a new growth catalyst, diversifies our revenue base and cash flow, and is expected to be significantly accretive in 2022." Compelling Strategic Rationale Strengthens Parkinson's disease portfolio with GOCOVRI® (amantadine) extended r

    $ADMS
    $SUPN
    Major Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

  • Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer

    ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus' proposed acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) expired at 11:59 p.m. on November 22, 2021. On October 21, 2021, Supernus and Adamas filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice. The expiration of the HSR Act waiting period satisfies one of the conditions to consummate the Offer (as defined below). The Off

    $ADMS
    $SUPN
    Major Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

  • Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio

    Acquisition of two marketed products diversifies and accelerates revenue and cash flowExpected to be significantly accretive in 2022Potential synergies of $60 million to $80 million in year one due to strong overlap with existing infrastructureTotal consideration up to $9.10 per share. Upfront cash payment of $8.10 per share with fully diluted equity value of approximately $400 million, plus $1.00 contingent value right based on net sales of GOCOVRI®Conference call and webcast today at 8:30 a.m. ET to discuss the transaction ROCKVILLE, Md. and EMERYVILLE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS),

    $ADMS
    $SUPN
    Major Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

$ADMS
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ADMS
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ADMS
 SEC Filings

See more

$ADMS
 Financials

Live finance-specific insights

See more

  • Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

    ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). "Adamas fits squarely within our corporate development strategy, adding a late-stage commercial product with significant revenue," said Jack Khattar, President and CEO of Supernus Pharmaceuticals. "In addition, the acquisition adds a new growth catalyst, diversifies our revenue base and cash flow, and is expected to be significantly accretive in 2022." Compelling Strategic Rationale Strengthens Parkinson's disease portfolio with GOCOVRI® (amantadine) extended r

    $ADMS
    $SUPN
    Major Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

  • Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio

    Acquisition of two marketed products diversifies and accelerates revenue and cash flowExpected to be significantly accretive in 2022Potential synergies of $60 million to $80 million in year one due to strong overlap with existing infrastructureTotal consideration up to $9.10 per share. Upfront cash payment of $8.10 per share with fully diluted equity value of approximately $400 million, plus $1.00 contingent value right based on net sales of GOCOVRI®Conference call and webcast today at 8:30 a.m. ET to discuss the transaction ROCKVILLE, Md. and EMERYVILLE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS),

    $ADMS
    $SUPN
    Major Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

  • Adamas Reports Second Quarter 2021 Financial Results

    Second quarter 2021 total revenues of $22.0 million, a 17% increase over second quarter 2020 GOCOVRI new paid prescriptions of 730, a 97% increase over second quarter 2020 Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the second quarter ended June 30, 2021, and recent corporate highlights. "We delivered a strong performance in the second quarter, with a robust increase in demand set to fuel future growth," said Neil F. McFarlane, Chief Executive Officer. "We remain on track to achieve our 2021 goals as we navigate the

    $ADMS
    Major Pharmaceuticals
    Health Care

$ADMS
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more